Michael P. Bevilacqua, M.D., Ph.D., Chief Executive Officer and Chief Scientific Officer
Dr. Bevilacqua, co-founder of Amicrobe, brings more than 30 years of experience as a medical scientist, inventor, and business executive. He has led successful research laboratories at Harvard Medical School and as a Howard Hughes investigator at UCSD Medical Center. As VP of Amgen, he built a division for inflammatory and immunological diseases. Dr. Bevilacqua has founded and / or worked with other start-up corporations in both therapeutics and diagnostics. His scientific work has led to many patents and publications.
Diego Benitez, Ph.D., Chief Technology Officer
Dr. Benitez, co-founder of Amicrobe, oversees technology development and intellectual property. Dr. Benitez is a synthetic chemist with expertise in catalytic synthesis and characterization of polymeric materials. He obtained his Ph.D. at the California Institute of Technology, under the direction of 2005 Chemistry Nobel Laureate Robert H. Grubbs and William A. Goddard, III. He later joined the laboratory of Sir J. Fraser Stoddart, at the California Nanosystems Institute, UCLA, where he managed interdisciplinary projects on polymeric supramolecular systems. Previously, Dr. Benitez served as CTO of NanoPacific Holdings, Inc.
Jarrod A. Hanson, Ph.D., Laboratory Head
Dr. Hanson leads the company’s biomaterials synthesis efforts as Laboratory Head, Synthetic Chemistry. He is responsible for the generation of Amicrobe’s biomaterials library, as well as the synthesis and formulation of product candidates. Dr. Hanson is a synthetic chemist with nearly a decade of experience in the synthesis and bioengineering methods that led to the foundation of Amicrobe’s R&D programs. Dr. Hanson obtained his Ph.D. under the direction of Prof. Timothy Deming at UCLA.
Daniel J. Huang, Business Operations
is Head of Business Operations. He oversees internal operations, as well as outside business interactions with contract research / manufacturing organizations. Daniel also contributes substantially to project management and business development efforts.
Timothy J. Deming, Ph.D., Consultant
Prof. Deming is a key consultant and co-founder. He has pioneered novel methods for the controlled synthesis of copolypeptides, publishing more than 70 articles and 16 patents. Prof. Deming’s research utilizes innovative chemistry techniques to synthesize and characterize complex biomaterials based on copolypeptides. Previously, he led successful research programs at UCSB and served as Chair of the UCLA Bioengineering Department, where he is currently a professor.
BOARD OF DIRECTORS
Michael Flesch, Chairman
Joseph A. Boystak
Albert Carnesale, Ph.D.
Michael P. Bevilacqua, M.D., Ph.D. (see above)